These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31591708)

  • 1. European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs.
    Neez E; Hwang TJ; Sahoo SA; Naci H
    Clin Pharmacol Ther; 2020 Mar; 107(3):541-552. PubMed ID: 31591708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.
    Khan S; Carter M
    Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582
    [No Abstract]   [Full Text] [Related]  

  • 3. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 5. Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations.
    Hanaizi Z; Kweder S; Thor S; Ribeiro S; Marcal A
    Ther Innov Regul Sci; 2023 Mar; 57(2):321-328. PubMed ID: 36307671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
    Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
    BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
    Detela G; Lodge A
    Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
    Teixeira T; Kweder SL; Saint-Raymond A
    Clin Pharmacol Ther; 2020 Mar; 107(3):507-513. PubMed ID: 31449664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of the European Medicines Agency's Development of Product-Specific Bioequivalence Guidelines.
    Sullivan JO; Blake K; Berntgen M; Salmonson T; Welink J;
    Clin Pharmacol Ther; 2018 Sep; 104(3):539-545. PubMed ID: 29319156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
    Nagai S
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis.
    Farina A; Moro F; Fasslrinner F; Sedghi A; Bromley M; Siepmann T
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00816. PubMed ID: 34232554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
    Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
    Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives.
    Marshall S; Madabushi R; Manolis E; Krudys K; Staab A; Dykstra K; Visser SAG
    CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):87-96. PubMed ID: 30411538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory policies on medicines for psychiatric disorders: is Europe on target?
    Barbui C; Garattini S
    Br J Psychiatry; 2007 Feb; 190():91-3. PubMed ID: 17267922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
    Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
    Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval.
    Djulbegovic B; Glasziou P; Klocksieben FA; Reljic T; VanDenBergh M; Mhaskar R; Ioannidis JPA; Chalmers I
    J Clin Epidemiol; 2018 Jun; 98():24-32. PubMed ID: 29432860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.